TY - JOUR T1 - Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results JF - The Journal of Rheumatology JO - J Rheumatol DO - 10.3899/jrheum.191209 SP - jrheum.191209 AU - Alexis Ogdie AU - Mei Liu AU - Meghan Glynn AU - Kelechi Emeanuru AU - Leslie R. Harrold AU - Sven Richter AU - Benoit Guerette AU - Philip J. Mease Y1 - 2020/11/15 UR - http://www.jrheum.org/content/early/2021/02/24/jrheum.191209.abstract N2 - Objective Therapeutic response was evaluated among new apremilast, methotrexate (MTX), or biologic disease-modifying antirheumatic drug (bDMARD) initiators with oligoarticular psoriatic arthritis (PsA). Methods Patients with oligoarticular PsA in the Corrona PsA/Spondyloarthritis Registry initiating treatment with apremilast, MTX, or bDMARD, and completing 6-month follow-up were included. Results In total, 150 patients initiated monotherapy (apremilast: n = 34; MTX: n = 15; bDMARD: n = 101). Apremilast initiators had higher baseline disease activity than MTX initiators. At follow-up, apremilast initiators experienced numerically greater disease activity improvements than MTX initiators and similar improvements to bDMARD initiators. Conclusion Findings suggest apremilast monotherapy is an effective option for patients with oligoarticular PsA. ER -